Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vote in favor of Your #1 Climbing boots Now - 2Six Flags Opens the Tallest, Fastest and Longest Roller Coaster in the World
- 3Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- 4What will the Artemis 2 astronauts eat during their historic moon mission? (video)
- 5South Carolina's measles outbreak reaches 434 cases
- They want better health care — so they're turning to crypto startups
- Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- Lebanon’s Hezbollah and Yemen’s Houthis join Iran in strike on Israel
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- The Incomparable Advanced cameras: Which One Will Win?
- Deadly attack on kindergarten reported in Sudan
- Astrophotographer captures spectacular photo of Antennae Galaxies dueling in deep space
- Energy security rifts widen in Europe
- Minneapolis ICE shooting: Woman dies after federal agent opens fire on her vehicle amid immigration crackdown
